Ординатура / Офтальмология / Английские материалы / Essentials in Ophthalmology Medical Retina_Holz, Speide_2005
.pdf
Subject Index
A
A2-E 21
ABCA4 gene |
37 |
|
|
|
Acquired hyperopia |
67 |
|
||
Acute idiopathic blind spot enlargement |
|
|||
syndrome (AIBSES) |
58 |
|
||
Acute macular neuroretinopathy (AMN) |
58 |
|||
Acute zonal occult outer retinopathy |
|
|||
(AZOOR) |
58 ff. |
|
|
|
Adult vitelliform macular dystrophy 27 |
|
|||
Adult-onset vitelliform macular dystrophy |
43 |
|||
Age-Related Eye Disease Study |
|
|||
(ARED study) |
112 |
|
|
|
Age-related macular degeneration |
|
|||
see macular degeneration |
|
|||
AIBSES see acute idiopathic blind spot |
|
|||
enlargement syndrome |
|
|||
AMN see acute macular neuroretinopathy |
|
|||
Anecortave acetate |
171 |
|
||
Angiogenesis |
101, 102 |
|
||
Antioxidant |
112 |
|
|
|
APO*E3 98 |
|
|
|
|
ARED study see Age-Related Eye Disease study Aspirin 174
Autosomal dominant cystoid macular oedema see macular oedema
Autosomal dominant drusen see drusen AZOOR see acute zonal occult outer retinopathy
B
Benign concentric annular macular
dystrophy |
45 |
|
Best disease |
27 |
|
Best vitelliform macular dystrophy |
|
|
(s. also Best disease) 35, 39 |
|
|
Branch retinal vein occlusion (BRVO) |
9, 146 |
|
Bruch’s membrane 99, 104 |
|
|
BRVO see branch retinal vein occlusion |
||
Bull’s eye macular dystrophy 45 |
|
|
Bullous detachment of the retina 83 |
|
|
Butterfly-shaped macular dystrophy |
48 |
|
C
b-Carotene 167 |
|
|
Central areolar choroidal dystrophy |
46 |
|
Central retinal vein occlusion (CRVO) |
146 |
|
Central serous chorioretinopathy (CSC) 77, 82, |
||
147 |
|
|
Choroidal folds |
65 |
|
Choroidal neoplasm 70 |
|
|
Choroidal neovascularization (CNV) |
11, 70, 95 |
|
– predominantly classic 129 |
|
|
– occult 11 |
|
|
– well-defined |
11 |
|
Chronic CSC see central serous chorioretinopathy
Chronic pre-phthisical ocular hypotony |
152 |
|
Cigarette smoking |
96 |
|
CNV see choroidal neovascularization |
|
|
COD1 43 |
|
|
Confocal scanning laser ophthalmoscopy |
21 |
|
C-reactive protein |
96 |
|
CRVO see central retinal vein occlusion Cyclooxygenase inhibitor 175
Cystoid macular oedema see macular oedema
D
Diabetic macular oedema see macular oedema Diabetic retinopathy 6, 144
Diffuse retina pigment epitheliopathy 82 Dorzolamide 174
Doyne honeycomb dystrophy 47 Drusen 25, 113, 166
– autosomal dominant 47
E
EFEMP1 gene 48
Epiretinal membrane 13, 15
Etaretin 175
Eye Disease Case Control Study 96
F
FAM study |
22 |
Fibronectin |
99 |
184 Subject Index
Fibrovascular pigment epithelium detachment 11
Fluorescein angiography 8
Foveal telangiectasias |
147 |
Fundus autofluorescence imaging 19ff. |
|
Fundus flavimaculatus |
27 |
Fundus pulverulentus |
48 |
G
GCAP1 43
Genistein 175
Geographic atrophy 22, 29, 115
H
High-resolution in vivo fundus autofluorescence
imaging |
31 |
Hypertension 96 |
|
Hypotony |
69 |
I
Idiopathic choroidal folds 69 Indocyanine green (ICG) angiography 80 Interference 2
Interferometry 2
Interferonα2a 173 Intracranial pressure 69 Ischaemia 101, 103
K
Kjellin’s syndrome 28
L
Laminin |
99 |
Lesion size |
133 |
Lipofuscin |
20, 97, 107 |
Lipofuscinogenesis 20 |
|
Low-dose chemotherapy 172 |
|
Lucentis |
169 |
Lutein 29, 168 |
|
M
Macugen 169
Macular degeneration, age-related 1, 11, 22, 144,
148 |
|
|
|
Macular dystrophy |
35 |
|
|
Macular hole 9 |
|
|
|
Macular oedema 1, 5, 12 |
|
||
– cystoid |
7 |
|
|
– – autosomal dominant |
44 |
||
– diabetic |
6, 144 |
|
|
– postoperative 15 |
|
|
|
– pseudophakic cystoid |
146 |
||
Macular pigment density |
29 |
||
Malattia Leventinese |
47 |
|
|
Matrix metalloproteinase inhibitor 171 |
||
Matrix metalloproteinases |
102 |
|
MCP see multifocal choroiditis and panuveitis |
||
Mean foveal thickness 5 |
|
|
Methotrexate |
172 |
|
MEWDS see multiple evanescent white dot |
||
syndrome |
|
|
Microperimetry 27 |
|
|
Müller cells |
7 |
|
Multifocal choroiditis and panuveitis |
||
(MCP) 58, 138 |
|
|
Multifocal pattern dystrophy |
48 |
|
Multiple evanescent white dot syndrome |
||
(MEWDS) |
58 |
|
N
Neovascular glaucoma |
147 |
Neovascular iris vessel |
147 |
North Carolina macular dystrophy 50, 51 |
|
N-retinylidene-N-retinylethanolamine (A2-E) 98 |
|
O
OCT see optical coherence tomography
Ocular histoplasmosis 138 |
|
Ocular hypertension |
153 |
Optic nerve pits 86 |
|
Optic neuropathay |
73 |
Optical coherence tomography (OCT) 1, 3, 88
– resolution 3 |
|
Orbital masses |
72 |
Oxidative damage 110, 165 |
|
Oxidative stress |
106 |
P
Pars plana vitrectomy 145
Pathologic myopia |
137 |
Pattern dystrophy |
48 |
PCV see polypoidal choroidal vasculopathy PDT 12
PEDF see pigment epithelium-derived factor
Pegabtanib |
169 |
|
|
|
Penetrating keratoplasty |
147 |
|
||
Peripherin/RDS gene |
44, 46, 49 |
|
||
Photocoagulation therapy |
89 |
|
||
Photodynamic therapy |
90, 129 |
|
||
Photopsia |
58 |
|
|
|
Pigment epithelial detachment 26 |
|
|||
Pigment epithelium-derived factor (PEDF) |
100, |
|||
109, 169, 171 |
|
|
|
|
Polypoidal choroidal vasculopathy (PCV) |
138 |
|||
Polyunsaturated fatty acid (PUFA) 108 |
|
|||
Posterior hyaloid traction |
8 |
|
||
Posterior scleritis 71 |
|
|
|
|
Postinjection infectious endophthalmitis |
155 |
|||
Subject Index |
185 |
Postinjection pseudoendophthalmitis |
155 |
Postinjection sterile endophthalmitis |
155 |
Prinonmastat 171 |
|
Progressive bifocal chorioretinal atrophy 49 Progressive cone dystrophy 41
Proliferative vitreoretinopathy 144, 151 Pseudophakic cystoid macular oedema
see macular oedema
PUFA see polyunsaturated fatty acid
R
Radial drusen |
47 |
|
Ranibizumab |
169 |
|
Reticular dystrophy |
48 |
|
Retinal folds |
66 |
|
Retinitis pigmentosa |
13 |
|
Rhegmatogenous retinal detachment 156
S
Scleral buckle |
72 |
|
Sorsby fundus dystrophy |
50 |
|
Staphylomal |
73 |
|
Stargardt disease 27, 35, 36 |
||
Steroid induced cataract |
156 |
|
Subretinal deposit 84 |
|
|
T
TAP study 130, 137
TIMP-3 gene |
48 |
Triamcinolone |
143, 153, 172 |
U
Ultrasonography 66
Ultrasound 1
Uveitis 10, 153
V
Vascular endothelial growth factor (VEGF) 102, 109, 169
VEGF see vascular endothelial growth factor Verteporfin Therapy with Altered Light
in Occult CNV (VALIO) study |
135 |
|
VIM study |
131 |
|
VIP study |
132, 133 |
|
Visual acuity 10 |
|
|
Vitamin A |
166 |
|
Vitamin C |
167 |
|
Vitamin E |
166, 167 |
|
Vitreomacular traction syndrome |
1 |
|
Vitreoretinal interface 13 |
|
|
VKH see Vogt-Koyanagi-Harada syndrome VMD2 gene 41, 44, 45 Vogt-Koyanagi-Harada syndrome (VKH) 72
X
X-linked juvenile retinoschisis 35, 38
Z
Zeaxanthin 29, 168
Zinc 166